Search

Fundamentals for a Systematic Approach to Mild and Moderate Inherited Bleeding Disorders: An EHA Consensus Report

Healthy subjects frequently report minor bleedings that are frequently ‘background noise’ of normality rather than a true disorder. Nevertheless, unexpected or unusual bleeding may be alarming.

HARMONY Alliance: Progress in Using Big Data Technology to Achieve Better Outcomes for Patients with Blood Cancers

Oct 26 2017

HARMONY Alliance: Progress in Using Big Data Technology to Achieve Better Outcomes for Patients with Blood Cancers: HARMONY Alliance is an unparalleled medicine offensive to battle blood cancers by using Big Data analyses.

EU funding crucial in allowing medical researchers across member states to collaborate in the development of new treatments

Feb 05 2018 Posted in Advocacy news Tagged Ulrich Jäger

In an article published in Science|Business, Prof.

EHA-SWG Scientific Meeting on Red Cell and Iron Metabolism Defects: From Basic Science to Clinical Case Application

Dates: October 12-14, 2023
Location: Budapest, Hungary
Chairs: A Taher & A Iolascon
Collaborating SWG: EHA Specialized Working Group on Red Cells and Iron

Registration is closed

RegistrationRegistration is closed. Visit this page for more information.

EHA-SWG Scientific Meeting on From aging hematopoietic stem cells to age-related diseases: opportunities for intervention Page

Dates: November 13-15, 2025
Location: Barcelona, Spain
Chairs: M Essers, E Laurenti, S Valetta, K Kirschner
Collaborating SWG: EHA Specialized Working Group (SWG) on Stem Cells and SWG on Aging

Registration will be open soon

Join leading experts in hematopoietic stem cell (HSC) biology and aging, and…

The European Hematology Association (EHA) announces an Invitation to Tender (ITT) for PCO services for the EHA Annual Congress

Oct 11 2021

The European Hematology Association (EHA) is pleased to inform the conference and meeting community that it will release an Invitation To Tender (ITT) for the appointment of a Professional Conference Organizer (PCO) for the EHA Congress in 2023.

The root of evil: pre-leukemic clones that survive chemotherapy are linked to a higher risk of leukemia recurrence

Jun 10 2016 Posted in Press releases

Acute myeloid leukemia (AML) is an aggressive form of blood cancer. Treatment with intensive chemotherapy often leads to a period of freedom from overt disease called a remission. However, recurrence of the disease is common.

Adding elotuzumab to standard treatment for multiple myeloma significantly reduced the risk of disease progression, with benefits sustained at two years

Jun 12 2015

ELOQUENT-2, which evaluated elotuzumab in combination with lenalidomide and dexamethasone, is the first Phase III study to demonstrate the benefit of directly activating the immune system in the treatment of patients with relapsed or refractory multiple myeloma.

EHA Statement: Our sustained solidarity with the hematology community in Ukraine

Feb 24 2023 Posted in EHA's actions for Ukraine

Friday, February 24 marks one year of war. The European Hematology Association (EHA) stands in solidarity with our colleagues and friends in Ukraine.

Ukraine Bridge Funding - information for applicants

Jan 09 2023 Posted in EHA's actions for Ukraine

The EHA Ukraine Bridge Funding Program is a 1-year non-clinical funding opportunity for Ukrainian hematologists and researchers in hematology (see press release here), now in collaboration with the American Society of Hematology, which will participate in funding and the selection…